Actively Recruiting
Study of Adrenergic Antibodies in Adults Aged 18 to 60 With Postural Tachycardia Syndrome Using IV Phenylephrine and Isoproterenol
Led by University of Calgary · Updated on 2026-05-05
125
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating Postural Tachycardia Syndrome POTS, a condition causing a rapid heart rate increase when standing and symptoms like palpitations, lightheadedness, and mental clouding. This study tests the idea that POTS patients aged 18 to 60 have more functional antibodies against adrenergic receptors compared to people without POTS. The research aims to understand the prevalence of these antibodies and their relationship to autoimmune illnesses and patient symptoms. Participants include POTS patients and healthy volunteers matched by age and gender. Both groups receive intravenous injections of phenylephrine and isoproterenol in small increasing doses. Researchers observe the blood pressure and heart rate responses to find the doses that raise systolic blood pressure or heart rate by 25 units respectively. This helps evaluate the physiological effects of adrenergic antibodies in living humans. During the study, participants undergo careful monitoring of heart rate and blood pressure through continuous measurements after each drug dose. Researchers record peak responses and wait for values to return to baseline before increasing doses. The main outcome measured is the proportion of subjects positive for alpha-1 adrenergic antibodies after one year. Secondary outcomes include antibody positivity by various clinical factors and the dose responses to the drugs. The total study period is one year with detailed assessments throughout.
CONDITIONS
Brief Title
POTS Adrenergic Ab (CIHR Aims #1&2)
Research Team
S
Satish R Raj, MD, MSCI
R
Robert S Sheldon, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here